Ano-uro-genital Guidelines Update
Melanoma Focus is delighted to announce the launch of the updated ano-uro-genital mucosal melanoma guidelines.
Charity News, Clinical Advances
Read more
News & Blog
Read all the latest updates on our charity, clinical advances in melanoma treatment, patient stories, fundraising and events.
For Press Releases & Media
MANIFEST: A UK Cancer Immunotherapy Response Research Platform
MANIFEST: A UK Cancer Immunotherapy Response Research Platform
Charity News, Clinical Advances
Read more
Tebentafusp Now Approved Across the UK for Eligible Patients with Advanced Uveal Melanoma
Tebentafusp Now Approved Across the UK for Eligible Patients with Advanced Uveal Melanoma
Charity News, Clinical Advances
Read more
Personalised Cancer Vaccine Shows Promising Long-term Results in Advanced Melanoma
At the 2026 international American Society of Clinical Oncology (ASCO) conference, 5 year patient outcomes from an initial cancer vaccine study in people with high risk melanomas were promising.
Charity News, Clinical Advances
Read more
Neoadjuvant Therapy has been Approved by NHS England
Melanoma Focus is thrilled to share that neoadjuvant therapy has been approved by NHS England for macroscopic stage 3 melanoma patients with operable disease spread skin or mucosal melanomas. This follows approval of neoadjuvant treatment in Scotland, Wales and Northern Ireland.
Melanoma Focus have supported the clinical community to gain access of this treatment.
Charity News, Clinical Advances
Read more
NICE’s draft guidance to currently NOT recommend lifileucel (TILs treatment) for previously treated unresectable or metastatic melanoma
The NICE Technology Appraisal Committee has published the draft guidance to currently NOT recommend lifileucel (TILs treatment) for previously treated unresectable or metastatic melanoma. This is not NICE's final guidance and the recommendations may change after the consultation which closes on 5pm on 22 January 2026.
Charity News, Clinical Advances
Read more
Consultation open: Skin Immunotherapy Side Effect Guidelines
We invite clinicians, nurses, organisations, patients & patient representatives to comment on the skin immunotherapy side effect guidelines, supporting information & patient information.
Charity News, Clinical Advances
Read more
Lab to Life: Innovations in Melanoma Research Conference UK
The University of Manchester is hosting its first Lab to Life: Innovations in Melanoma Research Conference UK, a conference focusing on translational research and treatment advances.
Clinical Advances
Read more
MelMarT-II Trial Recruitment Complete
The Melanoma Margins trial (MelMarT-II), an international surgical melanoma trial has recruited its 3000th patient.
Charity News, Clinical Advances
Read more
DANTE trial shows one year of immunotherapy treatment was similar to giving two years of treatment.
Professor Sarah Danson presented the results of the DANTE trial at the international 2025 ASCO conference in Chicago. Melanoma Focus were so pleased to support this important UK trial.
Clinical Advances
Read more
A New Personalised Treatment for Unresectable or Metastatic Melanoma Could Help Patients Live Longer
Lifileucel is a new type of personalised immunotherapy treatment, that uses the patient’s own immune system (the body’s natural defence) to attack their melanoma. The treatment is called tumour-infiltrating lymphocyte (TIL) therapy.
Clinical Advances
Read more
International Clinical Trials Day 2025
To mark International Clinical Trials Day, a melanoma patient and patient representative on the DETECTION-2 clinical trial, speaks to one of the lead investigators about the trial.
Charity News, Clinical Advances
Read more
- Page 1 of 4
- Next page